Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer

•Increasing BED in SBRT is associated with improved overall survival in renal cancer patients.•Increasing dose should be encouraged when safe.•Prospective investigation needed to validate. The National Cancer Database (NCDB) was queried (2004–2017) for patients with RCC who did not have surgical res...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational radiation oncology 2023-03, Vol.39, p.100592-100592, Article 100592
Main Authors: Tran, Kevin T., Chevli, Neil C., Messer, Jay A., Haque, Waqar, Farach, Andrew M., Satkunasivam, Raj, Zhang, Jun, Darcourt, Jorge, Lo, Simon S., Siva, Shankar, Butler, Edward B., Teh, Bin S.
Format: Article
Language:English
Subjects:
Biologically equivalent dose
Renal cancer
SBRT
Special Issue on Personalized Radiation Oncology
Edited by Daniel Zips, Pierre Blanchard
Stereotactic Body Radiotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Increasing BED in SBRT is associated with improved overall survival in renal cancer patients.•Increasing dose should be encouraged when safe.•Prospective investigation needed to validate. The National Cancer Database (NCDB) was queried (2004–2017) for patients with RCC who did not have surgical resection but received definitive SBRT. Kaplan-Meier analysis with log-rank test was used to evaluate overall survival (OS). Univariable (UVA) and multivariable (MVA) analysis were conducted using cox proportional hazard models to determine prognostic factors for OS. A total of 344 patients with median age 77 (IQR 70–85) were included in this study. Median BED3 was 180 Gy (IQR 126.03–233.97). Median OS was 90 months in the highest quartile compared to 36–52 months in the lower three quartiles (p 
ISSN:2405-6308
2405-6308
DOI:10.1016/j.ctro.2023.100592